Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

NCT04115306 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: PMD-026
DRUG: fulvestrant

Sponsor

Phoenix Molecular Designs